All stock lists
Novartis AG (New York Stock Exchange:NVS)
CH · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
153.81+2.69 (+1.78%)
Insider Score
––Not scored
NVS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Sound
From NVS’s reported statements · Q2 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $55.63B
- Net income
- $12.76B
- Net margin
- 22.9%
Leverage11 / 20
A manageable debt load.
- Total debt
- $49.01B
- Cash
- $7.62B
- Net debt / EBITDA
- 1.86x
Liquidity5 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $27.35B
- Current liabilities
- $31.75B
- Current ratio
- 0.86
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $18.39B
- Free cash flow
- $15.82B
- FCF margin
- 28.4%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 1905.0M
- Share growth (1y)
- -2.2%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NVS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 29, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 14.42 B | 13.52 B | 13.33 B | 14.36 B | 14.84 B | 13.62 B |
| Revenue Growth (YoY) | -2.82 % | -0.70 % | -1.64 % | 9.00 % | 15.26 % | 12.38 % |
| Cost of Revenue | 3.68 B | 3.46 B | 3.54 B | 3.54 B | 3.32 B | 3.23 B |
| Gross Profit | 10.74 B | 10.06 B | 9.79 B | 10.82 B | 11.51 B | 10.39 B |
| SG&A Expense | 3.24 B | 3.14 B | 3.44 B | 3.31 B | 3.44 B | 3.06 B |
| R&D Expense | 2.76 B | 2.74 B | 2.84 B | 2.94 B | 2.73 B | 2.37 B |
| Operating Expenses | 6.00 B | 5.83 B | 6.27 B | 6.32 B | 6.65 B | 5.73 B |
| Operating Income | 4.74 B | 4.24 B | 3.52 B | 4.50 B | 4.86 B | 4.66 B |
| Pretax Income | 4.27 B | 3.84 B | 3.22 B | 4.20 B | 4.53 B | 4.41 B |
| Tax Provision | 1.01 B | 683.00 M | 813.94 M | 266.00 M | 507.00 M | 798.00 M |
| Net Income | 3.27 B | 3.16 B | 2.41 B | 3.93 B | 4.04 B | 3.61 B |
| EPS (Basic) | 1.71 | 1.65 | 1.26 | 2.04 | 2.07 | 1.83 |
| EPS (Diluted) | 1.71 | 1.65 | 1.25 | 2.02 | 2.06 | 1.82 |
| Shares Outstanding | 1.91 B | 1.91 B | 1.91 B | 1.93 B | 1.95 B | 1.97 B |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.